Topotarget, results keep rolling in

Practically every day these weeks, new surveys and studies are being published about Belinostat. Today,  a study regarding the effect of belinostat in International Journal of Gynecological Cancer titled:

Conclusions: Belinostat, carboplatin, and paclitaxel combined was reasonably well tolerated and demonstrated clinical benefit in heavily-pretreated patients with EOC. The addition of belinostat to this platinum-based regimen represents a novel approach to EOC therapy and warrants further exploration.